Curious whether @pharmdca or @phillyrealty have looked at $rmed. It's had a rough year and is near lows, but both devices (esp. DABRA) look interesting. The chart is coiling up a bit, but there are no near-term catalysts as far as I can see. Cash is 2x market cap. 1/2

There are some engineering fixes they need to implement for the catheter of DABRA (for better shelf-life & less kinking). According to the CC, they are hoping to have them in place by early 21. Without cash, that would be a pretty big red flag. But they have cash.

Thoughts? 2/2

I should finished this thread with my "yikes, never mind" reaction once I came to it:

11/20/2019: 13,407,995 shares outstanding.
8/7/2020: 72,468,337 shares outstanding.

56M warrants added since May 2020 not counted in that total (exercisable at .35 & .45).